United States: Ten Years Of Biosimilars In Europe

Last Updated: December 11 2015
Article by Aron Fischer and Jacob F. Siegel

This fall marks the tenth anniversary of the effective date of the European Medicines Agency's Guideline on Similar Biological Medicinal Products. As this blog noted previously, the EU's biosimilar pathway both preceded the U.S. pathway created in 2010 and came into use more quickly. Over the past ten years, the EMA has approved 19 biosimilars under the guidelines, corresponding to 6 different reference drugs, in six categories of biologics: epoetins, filgrastims, follitropins, growth hormones, insulins, and monoclonal antibodies.  The EMA's Committee for Medicinal Products for Human Use recently recommended granting marketing authorization for a biosimilar of Enbrel, a dimeric fusion protein, which would constitute a seventh category.  Although the U.S., with its larger and more homogenous pharmaceutical market, is unlikely to follow the exact same path as Europe, the European experience is relevant in assessing the future of biosimilars in the United States.

Biosimilar Products Approved by the EMA as of December 7, 2015 (1)

Biosimilar Trade Name Marketer Active Substance Reference Drug Year of Approval
Abseamed Medice epoetin alfa Eprex/Erypo 2007
Binocrit Sandoz epotein alfa Eprex/Erypo 2007
Epoetin Alfa Hexal Hexal epotein alfa Eprex/Erypo 2007
Retacrit (2) Hospira epotein zeta Eprex/Erypo 2007
Silapo Stada epotein zeta Eprex/Erypo 2007
Accofil Accord filgrastim Neupogen 2014
Biograstim AbZ-Pharma filgrastim Neupogen 2008
Filgrastim Hexal Hexal filgrastim Neupogen 2009
Grastofil Apotex filgrastim Neupogen 2013
Nivestim Hospira filgrastim Neupogen 2010
Ratiograstim Ratiopharm filgrastim Neupogen 2008
Tevagrastim Teva filgrastim Neupogen 2008
Zarzio (3) Sandoz filgrastim Neupogen 2009
Bemfola Finox follitropin alfa GONAL-f 2014
Ovaleap Teva follitropin alfa GONAL-f 2013
Growth Hormones
Omnitrope (4) Sandoz somatropin Genotropin 2006
Abasaglar (5) Eli Lilly insulin glargine Lantus 2014
Monoclonal Antibodies
Inflectra Hospira infliximab Remicade 2013
Remsima Celltrion infliximab Remicade 2013
  1. (1) Two additional biosimilars were approved by the EMA but subsequently had their authorizations withdrawn.
  2. (2) BPCIA application to market in the United States rejected by the FDA
  3. (3) Approved in the United States as a biosimilar under the BPCIA with trade name Zarxio
  4. (4) Approved in the United States under the 505(b)(2) pathway
  5. (5) Original EU trade name was Abasria; tentatively approved in U.S. under 505(b)(2) pathway with trade name Basaglar

Market adoption of biosimilars

Unlike generic small-molecule drugs, which generally replace brand-name drugs once they are approved, adoption of biosimilars in the EU has been mixed, ranging greatly between countries and between products.  This is because while the authorization to market biosimilars is provided centrally by the EMA, each country retains control over substitution policies, i.e. recommendations as to whether a biosimilar should be used interchangeably with its reference medicine.  Thus, for example, a recent study by the IMS Institute for Healthcare Informatics found that biosimilar penetration in 2013 for G-CSF (filgrastim) ranged from 2% of treatment days in Belgium to nearly 100% in Croatia, Czech Republic, Hungary, and Romania. The IMS study attributes differences in the uptake of biosimilars—and differences in price competition—to local practices, practices in turn influenced by national funding schemes and the actions of payers.

Product Specific Guidelines

The EMA has established specific guidelines detailing requirements for regulatory approval for each of the categories of biosimilars currently approved, as well as for biosimilar products containing interferon alpha, interferon beta and low-molecular-weight heparins. Category-based guidelines are valuable in the development of standards for biologics, since the complexity of structure and glycosylation differs greatly across categories of biologic products. In the next several years, as the FDA considers applications for biosimilars of varying types, we can expect that the U.S. will begin to develop category-specific policies as well.

Naming schemes for biosimilars

In Europe, biosimilars are generally referred to by their trade names, which are different from those of the brand-name reference drug, but the non-proprietary names of European biosimilars are identical to those of their reference drug.  For instance, the European packaging for Zarzio (the European trade name for Zarxio) identifies the product by that trade name and by its International Nonproprietary Names name, filgrastim. Filgrastim is the same INN name used for the reference product, Neupogen, even though the two products are (bio)similar rather than identical. The FDA's recently issued draft guidance, by contrast, requires the addition of a randomly-assigned suffix for all biologic products.  It results in different non-proprietary names for biosimilars and their reference drugs. Under the proposed U.S. naming scheme, for example, Zarxio will be identified as "filgrastim-bflm," while Neupogen will be assigned the name "filgrastim-jcwp."

The next several years:

The U.S. has taken a more cautious pace to the approval of biosimilar medications than the EU took in its first few years. While the U.S. biosimilar statute became law in 2010 and the FDA's first guidance on biosimilars was released in 2012, to date only one product (Zarxio) has been approved in the U.S. as a biosimilar. The number of biosimilar applications pending FDA review indicates that the next several years may be a time of rapid development in the regulation of U.S. biosimilars – although the FDA's most recent publicly announced decision, rejecting Hospira's application for a biosimilar version of Amgen's Epogen (EPO), suggests that the FDA is taking a cautious approach and will not approve a proposed biosimilar even when it is already marketed in the EU.  It remains to be seen to what extent the U.S. regulatory pathway follows the contours of the European model.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.